Pulmonx Gets New Chief Exec

Pulmonology device company, Pulmonx Corporation, has a new boss, Glen French, who has joined the company as President, Chief Executive Officer and member of the Board of Directors.


Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that target lung disease. The company’s flagship product is the Zephyr® EBV (Endobronchial Valve), a minimally invasive, valve-based treatment for severe emphysema that has been proven over a decade of clinical experience to significantly improve lung function, exercise tolerance and quality of life for patients receiving treatment. The device remains investigational in the United States by the way.

The procedure involves the insertion of tiny, one-way valves in the lungs to block airflow to hyperinflated regions to achieve lung volume reduction. As a result, the remaining healthy regions may function more efficiently, enabling better breathing and improving quality of life.

New President and CEO Mr. French comes from the pulmonology, respiratory and endoscopic business, having most recently been CEO of ApniCure, a developer of proprietary devices for the treatment of obstructive sleep apnea (OSA) and other sleep disorders.

Company comments 

“Glen has spent more than 15 years leading companies focused on the development of interventional pulmonology products. Glen’s deep market knowledge and experience will be invaluable as we continue to build momentum for Pulmonx’s products in the market,” said Dr. Rodney Perkins, Pulmonx Founder and Chairman of the Board.

Incumbent comments

“There is a large need for effective, less invasive treatments for severe emphysema, and Pulmonx offers compelling technologies that fill this gap,” said Mr. French. “Through our good work we will help reduce the suffering and restore the quality of life of emphysema patients worldwide with both existing and new therapies.”

Source: Pulmonx Corporation

Share your thoughts

Your email address will not be published. Required fields are marked *